Tel: +1 603 252 2274
Dr. Tillman Gerngross joined SVLS in 2006. He is involved in the review of investment opportunities in the therapeutic protein and antibody space as well as evaluating new startup opportunities.
Dr. Gerngross is the co-founder and CEO of Adimab, a SVLSF IV portfolio company. He is also the co-founder of Arsanis, a company focused on the development of antibodies against infectious diseases (SVLSF V). Previously, he was a co-founder of GlycoFi, Inc. (SVLSF III) and served as the company's Chief Scientific Officer until its acquisition by Merck and Co in June of 2006. In addition, Dr. Gerngross holds faculty positions at the Engineering School at Dartmouth College, as well as the Departments of Biology and Chemistry.
Dr. Gerngross is a native of Austria where he obtained a M.S. degree in Chemical Engineering and a Ph.D. in Molecular Biology from the Technical University of Vienna. From 1989-93 he was a visiting scientist and later Postdoctoral Fellow at MIT.